JP2023055871A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2023055871A5 JP2023055871A5 JP2023014793A JP2023014793A JP2023055871A5 JP 2023055871 A5 JP2023055871 A5 JP 2023055871A5 JP 2023014793 A JP2023014793 A JP 2023014793A JP 2023014793 A JP2023014793 A JP 2023014793A JP 2023055871 A5 JP2023055871 A5 JP 2023055871A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutical composition
- use according
- composition
- antibody
- cancer
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2024189529A JP2025016606A (ja) | 2014-09-16 | 2024-10-29 | 抗ｎｋｇ２ａ抗体を使用した治療計画 |
Applications Claiming Priority (11)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201462050948P | 2014-09-16 | 2014-09-16 | |
| US62/050,948 | 2014-09-16 | ||
| US201462067642P | 2014-10-23 | 2014-10-23 | |
| US62/067,642 | 2014-10-23 | ||
| US201462083929P | 2014-11-25 | 2014-11-25 | |
| US62/083,929 | 2014-11-25 | ||
| US201462093124P | 2014-12-17 | 2014-12-17 | |
| US201462093141P | 2014-12-17 | 2014-12-17 | |
| US62/093,124 | 2014-12-17 | ||
| US62/093,141 | 2014-12-17 | ||
| JP2020166883A JP2021008487A (ja) | 2014-09-16 | 2020-10-01 | 抗ｎｋｇ２ａ抗体を使用した治療計画 |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020166883A Division JP2021008487A (ja) | 2014-09-16 | 2020-10-01 | 抗ｎｋｇ２ａ抗体を使用した治療計画 |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024189529A Division JP2025016606A (ja) | 2014-09-16 | 2024-10-29 | 抗ｎｋｇ２ａ抗体を使用した治療計画 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2023055871A JP2023055871A (ja) | 2023-04-18 |
| JP2023055871A5 true JP2023055871A5 (https=) | 2023-08-08 |
| JP7580506B2 JP7580506B2 (ja) | 2024-11-11 |
Family
ID=54105801
Family Applications (4)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017514485A Pending JP2017538660A (ja) | 2014-09-16 | 2015-09-15 | 抗ｎｋｇ２ａ抗体を使用した治療計画 |
| JP2020166883A Pending JP2021008487A (ja) | 2014-09-16 | 2020-10-01 | 抗ｎｋｇ２ａ抗体を使用した治療計画 |
| JP2023014793A Active JP7580506B2 (ja) | 2014-09-16 | 2023-02-02 | 抗ｎｋｇ２ａ抗体を使用した治療計画 |
| JP2024189529A Pending JP2025016606A (ja) | 2014-09-16 | 2024-10-29 | 抗ｎｋｇ２ａ抗体を使用した治療計画 |
Family Applications Before (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017514485A Pending JP2017538660A (ja) | 2014-09-16 | 2015-09-15 | 抗ｎｋｇ２ａ抗体を使用した治療計画 |
| JP2020166883A Pending JP2021008487A (ja) | 2014-09-16 | 2020-10-01 | 抗ｎｋｇ２ａ抗体を使用した治療計画 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024189529A Pending JP2025016606A (ja) | 2014-09-16 | 2024-10-29 | 抗ｎｋｇ２ａ抗体を使用した治療計画 |
Country Status (14)
| Country | Link |
|---|---|
| US (4) | US10676523B2 (https=) |
| EP (1) | EP3193929B1 (https=) |
| JP (4) | JP2017538660A (https=) |
| KR (2) | KR20240141862A (https=) |
| CN (1) | CN107074950A (https=) |
| AU (3) | AU2015316993B2 (https=) |
| CA (1) | CA2959463A1 (https=) |
| DK (1) | DK3193929T3 (https=) |
| ES (1) | ES2742456T3 (https=) |
| HU (1) | HUE044704T2 (https=) |
| IL (1) | IL250672B (https=) |
| PL (1) | PL3193929T3 (https=) |
| SG (2) | SG10202007781TA (https=) |
| WO (1) | WO2016041947A1 (https=) |
Families Citing this family (56)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3409289B1 (en) | 2010-02-26 | 2020-09-30 | Novo Nordisk A/S | Stable antibody containing compositions |
| KR102047248B1 (ko) | 2011-06-17 | 2019-11-21 | 노보 노르디스크 에이/에스 | 침식성 세포의 선택적 제거 |
| SG10202007781TA (en) | 2014-09-16 | 2020-09-29 | Innate Pharma | Treatment Regimens Using Anti-NKG2A Antibodies |
| AU2015316991B2 (en) | 2014-09-16 | 2021-04-01 | Innate Pharma | Neutralization of inhibitory pathways in lymphocytes |
| US10329348B2 (en) | 2014-10-23 | 2019-06-25 | Innate Pharma | Treatment of cancers using anti-NKG2A agents |
| US9708412B2 (en) | 2015-05-21 | 2017-07-18 | Harpoon Therapeutics, Inc. | Trispecific binding proteins and methods of use |
| US10736963B2 (en) | 2015-07-24 | 2020-08-11 | Innate Pharma | Methods for detecting tissue infiltrating NK cells |
| SI3405495T1 (sl) | 2016-01-21 | 2021-08-31 | Innate Pharma | Nevtralizacija inhibitornih poti v limfocitih |
| US11623958B2 (en) | 2016-05-20 | 2023-04-11 | Harpoon Therapeutics, Inc. | Single chain variable fragment CD3 binding proteins |
| EP3529277A1 (en) | 2016-10-21 | 2019-08-28 | Innate Pharma | Treatment with anti-kir3dl2 agents |
| EP3621994A4 (en) | 2017-05-12 | 2020-12-30 | Harpoon Therapeutics, Inc. | MESOTHELIN BINDING PROTEINS |
| US11447545B2 (en) | 2017-07-10 | 2022-09-20 | Innate Pharma | Combination therapy using antibody to human Siglec-9 and antibody to human NKG2A for treating cancer |
| IL315737A (en) | 2017-10-13 | 2024-11-01 | Harpoon Therapeutics Inc | B-cell maturation antigen-binding proteins |
| MX2020003915A (es) | 2017-10-13 | 2020-10-08 | Harpoon Therapeutics Inc | Proteinas trispecificas y metodos de uso. |
| WO2019175182A1 (en) * | 2018-03-13 | 2019-09-19 | Innate Pharma | Treatment of head and neck cancer |
| EP3768715A1 (en) | 2018-03-23 | 2021-01-27 | Bristol-Myers Squibb Company | Antibodies against mica and/or micb and uses thereof |
| EA202092696A1 (ru) | 2018-05-15 | 2021-04-05 | Медиммун Лимитед | Лечение рака |
| US12195544B2 (en) | 2018-09-21 | 2025-01-14 | Harpoon Therapeutics, Inc. | EGFR binding proteins and methods of use |
| US10815311B2 (en) | 2018-09-25 | 2020-10-27 | Harpoon Therapeutics, Inc. | DLL3 binding proteins and methods of use |
| US12534526B2 (en) | 2018-11-07 | 2026-01-27 | Shanghai Hyamab Biotech Co., Ltd. | NKG2A antibody, preparation method therefor and application thereof |
| CN113316590B (zh) | 2018-11-16 | 2025-02-28 | 百时美施贵宝公司 | 抗nkg2a抗体及其用途 |
| WO2020205440A1 (en) * | 2019-03-29 | 2020-10-08 | Dren Bio, Inc. | Methods of reducing large granular lymphocyte and natural killer cell levels |
| KR20220016155A (ko) | 2019-05-30 | 2022-02-08 | 브리스톨-마이어스 스큅 컴퍼니 | 면역-종양학 (i-o) 요법에 적합한 대상체를 확인하는 방법 |
| US20220363760A1 (en) | 2019-05-30 | 2022-11-17 | Bristol-Myers Squibb Company | Multi-tumor gene signature for suitability to immuno-oncology therapy |
| WO2020243570A1 (en) | 2019-05-30 | 2020-12-03 | Bristol-Myers Squibb Company | Cell localization signature and combination therapy |
| WO2021024020A1 (en) | 2019-08-06 | 2021-02-11 | Astellas Pharma Inc. | Combination therapy involving antibodies against claudin 18.2 and immune checkpoint inhibitors for treatment of cancer |
| CN114599372A (zh) | 2019-11-04 | 2022-06-07 | 阿斯利康(瑞典)有限公司 | 用于治疗癌症的组合疗法 |
| CN113583127A (zh) * | 2020-04-30 | 2021-11-02 | 迈威(上海)生物科技股份有限公司 | 一种靶向nkg2a和pd-l1的双特异性抗体及应用 |
| CN116096754A (zh) * | 2020-05-04 | 2023-05-09 | 免疫里森公司 | 前体三特异性抗体构建体及其使用方法 |
| US20230348854A1 (en) * | 2020-05-08 | 2023-11-02 | Seattle Children's Hospital D/B/A Seattle Children's Research Institute | Chimeric antigen receptors (cars) targeting natural killer cells |
| KR20230035576A (ko) | 2020-07-07 | 2023-03-14 | 비온테크 에스이 | Hpv 양성 암 치료용 rna |
| AU2021334361A1 (en) | 2020-08-31 | 2023-05-11 | Bristol-Myers Squibb Company | Cell localization signature and immunotherapy |
| KR20230104611A (ko) | 2020-09-30 | 2023-07-10 | 드렌 바이오, 인크. | 항-cd94 항체 및 이의 사용 방법 |
| WO2022120179A1 (en) | 2020-12-03 | 2022-06-09 | Bristol-Myers Squibb Company | Multi-tumor gene signatures and uses thereof |
| AR124414A1 (es) | 2020-12-18 | 2023-03-22 | Century Therapeutics Inc | Sistema de receptor de antígeno quimérico con especificidad de receptor adaptable |
| WO2022135666A1 (en) | 2020-12-21 | 2022-06-30 | BioNTech SE | Treatment schedule for cytokine proteins |
| TW202245808A (zh) | 2020-12-21 | 2022-12-01 | 德商拜恩迪克公司 | 用於治療癌症之治療性ｒｎａ |
| WO2022135667A1 (en) | 2020-12-21 | 2022-06-30 | BioNTech SE | Therapeutic rna for treating cancer |
| JP2024501029A (ja) | 2020-12-28 | 2024-01-10 | ブリストル－マイヤーズ スクイブ カンパニー | Ｐｄ１／ｐｄ－ｌ１抗体の皮下投与 |
| US20220233693A1 (en) | 2020-12-28 | 2022-07-28 | Bristol-Myers Squibb Company | Antibody Compositions and Methods of Use Thereof |
| EP4314068A1 (en) | 2021-04-02 | 2024-02-07 | The Regents Of The University Of California | Antibodies against cleaved cdcp1 and uses thereof |
| WO2022253805A1 (en) * | 2021-06-01 | 2022-12-08 | Symphogen A/S | Anti-nkg2a antibodies and compositions |
| CA3225254A1 (en) | 2021-07-13 | 2023-01-19 | BioNTech SE | Multispecific binding agents against cd40 and cd137 in combination therapy for cancer |
| TW202333802A (zh) | 2021-10-11 | 2023-09-01 | 德商拜恩迪克公司 | 用於肺癌之治療性rna(二) |
| WO2023178329A1 (en) | 2022-03-18 | 2023-09-21 | Bristol-Myers Squibb Company | Methods of isolating polypeptides |
| KR20250022071A (ko) | 2022-06-02 | 2025-02-14 | 브리스톨-마이어스 스큅 컴퍼니 | 항체 조성물 및 이의 이용 방법 |
| JP2026501506A (ja) | 2022-12-14 | 2026-01-16 | アステラス・ファーマ・ヨーロッパ・ベスローデン・フェンノートシャップ | Ｃｌｄｎ１８．２及びｃｄ３に結合する二重特異性結合剤並びに免疫チェックポイント阻害剤を含む併用療法 |
| EP4649173A1 (en) | 2023-01-13 | 2025-11-19 | Akrivia Biomedics Limited | Method of profiling diseases |
| WO2024196952A1 (en) | 2023-03-20 | 2024-09-26 | Bristol-Myers Squibb Company | Tumor subtype assessment for cancer therapy |
| WO2025038763A1 (en) | 2023-08-15 | 2025-02-20 | Bristol-Myers Squibb Company | Ceramic hydroxyapatite chromatography flow through method |
| TW202541837A (zh) | 2023-12-08 | 2025-11-01 | 日商安斯泰來製藥公司 | 含有結合至cldn18.2和cd3之雙特異性結合劑和穩定或增加cldn18.2表現之藥劑之組合療法 |
| WO2025120866A1 (en) | 2023-12-08 | 2025-06-12 | Astellas Pharma Inc. | Combination therapy involving bispecific binding agents binding to cldn18.2 and cd3 and agents stabilizing or increasing expression of cldn18.2 |
| WO2026033885A1 (en) | 2024-08-08 | 2026-02-12 | Astellas Pharma Inc. | Combination therapy involving bispecific binding agents binding to cldn18.2 and cd3 and agents stabilizing or increasing expression of cldn18.2 |
| WO2025120867A1 (en) | 2023-12-08 | 2025-06-12 | Astellas Pharma Inc. | Combination therapy involving bispecific binding agents binding to cldn18.2 and cd3 and anti-vegfr2 antibodies |
| WO2025145207A1 (en) | 2023-12-29 | 2025-07-03 | Bristol-Myers Squibb Company | Combination therapy of kras inhibitor and treg-depleting agent |
| NL2037811B1 (en) | 2024-05-29 | 2025-12-12 | Univ Oslo | Treatment for Cancer |
Family Cites Families (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB9725764D0 (en) | 1997-12-04 | 1998-02-04 | Isis Innovation | HLA-E binding |
| US20030095965A1 (en) | 2001-05-02 | 2003-05-22 | Katrien Van Beneden | Antibodies to Ly49E and CD94/NKG2 receptors |
| CN101107269B (zh) * | 2004-12-28 | 2012-10-31 | 依奈特制药公司 | 抗nkg2a的单克隆抗体 |
| PT1831258E (pt) | 2004-12-28 | 2016-01-07 | Univ Genova | Anticorpos monoclonais contra nkg2a |
| MX2008015830A (es) | 2006-06-30 | 2009-01-09 | Novo Nordisk As | Anticuerpos anti-nkg2a y usos de los mismos. |
| KR20100110864A (ko) | 2008-01-24 | 2010-10-13 | 노보 노르디스크 에이/에스 | 인간화된 항-인간 ｎｋｇ2ａ 모노클로날 항체 |
| WO2010129033A2 (en) | 2009-04-29 | 2010-11-11 | Calmune Corporation | Modified antibodies for passive immunotherapy |
| EP3409289B1 (en) | 2010-02-26 | 2020-09-30 | Novo Nordisk A/S | Stable antibody containing compositions |
| KR102047248B1 (ko) | 2011-06-17 | 2019-11-21 | 노보 노르디스크 에이/에스 | 침식성 세포의 선택적 제거 |
| RU2017105425A (ru) | 2014-08-28 | 2018-09-28 | Академиш Зикенхёйс Лейден Х.О.Д.Н. Люмк | Комбинации антитела против cd94/nkg2a и/или cd94/nkg2b и вакцины |
| AU2015316991B2 (en) | 2014-09-16 | 2021-04-01 | Innate Pharma | Neutralization of inhibitory pathways in lymphocytes |
| SG10202007781TA (en) | 2014-09-16 | 2020-09-29 | Innate Pharma | Treatment Regimens Using Anti-NKG2A Antibodies |
| US10329348B2 (en) | 2014-10-23 | 2019-06-25 | Innate Pharma | Treatment of cancers using anti-NKG2A agents |
| SI3405495T1 (sl) | 2016-01-21 | 2021-08-31 | Innate Pharma | Nevtralizacija inhibitornih poti v limfocitih |
| WO2019175182A1 (en) | 2018-03-13 | 2019-09-19 | Innate Pharma | Treatment of head and neck cancer |
| EA202092696A1 (ru) | 2018-05-15 | 2021-04-05 | Медиммун Лимитед | Лечение рака |
-
2015
- 2015-09-15 SG SG10202007781TA patent/SG10202007781TA/en unknown
- 2015-09-15 US US15/511,792 patent/US10676523B2/en active Active
- 2015-09-15 DK DK15763016.1T patent/DK3193929T3/da active
- 2015-09-15 CN CN201580050103.1A patent/CN107074950A/zh active Pending
- 2015-09-15 KR KR1020247031251A patent/KR20240141862A/ko active Pending
- 2015-09-15 CA CA2959463A patent/CA2959463A1/en active Pending
- 2015-09-15 AU AU2015316993A patent/AU2015316993B2/en active Active
- 2015-09-15 ES ES15763016T patent/ES2742456T3/es active Active
- 2015-09-15 JP JP2017514485A patent/JP2017538660A/ja active Pending
- 2015-09-15 SG SG11201701387SA patent/SG11201701387SA/en unknown
- 2015-09-15 WO PCT/EP2015/071073 patent/WO2016041947A1/en not_active Ceased
- 2015-09-15 PL PL15763016T patent/PL3193929T3/pl unknown
- 2015-09-15 EP EP15763016.1A patent/EP3193929B1/en active Active
- 2015-09-15 KR KR1020177008837A patent/KR20170068458A/ko not_active Ceased
- 2015-09-15 HU HUE15763016 patent/HUE044704T2/hu unknown
-
2017
- 2017-02-19 IL IL250672A patent/IL250672B/en active IP Right Grant
-
2020
- 2020-06-08 US US16/894,937 patent/US20200299383A1/en not_active Abandoned
- 2020-10-01 JP JP2020166883A patent/JP2021008487A/ja active Pending
-
2021
- 2021-04-08 US US17/225,160 patent/US12037392B2/en active Active
- 2021-06-07 AU AU2021203744A patent/AU2021203744B2/en active Active
-
2023
- 2023-02-02 JP JP2023014793A patent/JP7580506B2/ja active Active
-
2024
- 2024-07-15 US US18/772,517 patent/US20240368281A1/en active Pending
- 2024-10-29 JP JP2024189529A patent/JP2025016606A/ja active Pending
-
2025
- 2025-07-17 AU AU2025205563A patent/AU2025205563A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2023055871A5 (https=) | ||
| JP2025016606A5 (https=) | ||
| KR101905208B1 (ko) | Cd38을 특이적으로 인식하는 항체 및 보르테조밉을 함유하는 항종양 조합물 | |
| TWI436770B (zh) | 包含專一性辨識ｃｄ３８之抗體及阿糖胞苷（ｃｙｔａｒａｂｉｎｅ）之抗腫瘤組合 | |
| JP6215429B2 (ja) | Ｃｄ３８を特異的に認識する抗体とシクロホスファミドとを含有する抗腫瘍組合せ | |
| KR101733253B1 (ko) | Ｃｄ３８을 특이적으로 인식하는 항체 및 빈크리스틴을 함유하는 항종양 조합물 | |
| TW201023855A (en) | Antitumor combinations containing antibodies recognizing specifically CD38 and melphalan | |
| JP2009518441A5 (https=) | ||
| CN105407921A (zh) | 包含抗cd38抗体和卡非佐米的组合物 | |
| JP2021512107A5 (https=) | ||
| JP2024537288A5 (https=) | ||
| JP2023506779A5 (https=) | ||
| HK1164152A (en) | Antitumor combinations containing antibodies recognizing specifically cd38 and cytarabine | |
| HK1164154B (en) | Antitumor combinations containing antibodies recognizing specifically cd38 and cylophosphamide | |
| HK1185022A (en) | Antitumor combinations containing antibodies recognizing specifically cd38 and bortezomib | |
| HK1164165B (en) | Antitumor combinations containing antibodies recognizing specifically cd38 and melphalan |